The role of FSCN1 in migration and invasion of pituitary adenomas
The role of FSCN1 in migration and invasion of pituitary adenomas
复制标题
FSCN1在垂体腺瘤迁移和侵袭中的作用
DOI：
10.1016/j.mce.2015.10.021
复制
发表时间：
2016-01-05
影响因子：
4.1
通讯作者：
Zhang, Yazhuo
中科院分区：
文献类型：
--
作者：
Liu, Chunhui;Gao, Hua;Zhang, Yazhuo
PA 中侵袭或恶性行为的预测仍然具有挑战性。 FSCN1 是一种肌动蛋白捆绑蛋白，与各种癌症类型的死亡率和转移风险增加相关。该研究的目的是评估 312 例 PA 病例中 FSCN1 的表达，并分析其与临床病理特征和 PA 侵袭的关系，从而作为癌症侵袭的促进者。在无功能 PA (NFPA) 中，侵入性组 (IPA) 中 FSCN1 核阳性病例为 53/97，非侵入性组 (nIPA) 中 FSCN1 核阳性病例为 21/115 (x(2) = 30.65，p = 0.004）。 FSCN1 细胞质阳性病例在 IPA 中为 36/97，在 nIPA 中为 8/107 (x(2) = 29.09，p = 0.000）。在生长激素腺瘤 (GHomas) 中，IPA 中 FSCN1 核阳性率为 10/13，nIPA 中 3/37 (x(2) = 23.67，p = 0.000）。 FSCN1 细胞质阳性在 IPA 中为 8/13，在 nIPA 中为 2/37（表 3 x(2) = 18.94，p = 0.000）。总体而言，FSCN1 表达和肿瘤大小之间存在显着差异（x(2) = 46.21，p = 0.000），而不是年龄（x(2) = 2.09，p = 0.148）。在FSCN1高表达组中，27/137例（19.7%）出现肿瘤复发，而FSCN1低表达组中有10/175例（5.7%）出现肿瘤复发（x(2) = 14.40 p = 0.000）。通过transwells测试，FSCN1的减少抑制了GH3细胞的侵袭水平。此外，FSCN1的减少可以明显下调Notch1和DLL3的水平。我们的数据可能有助于确定 FSCN1 是否可以作为 PA 侵袭和复发的预测因子。 (C) 2015 Elsevier Ireland Ltd. 保留所有权利。
The prediction of invasion or malignant behavior in PAs remains challenging. FSCN1, an actin-bundling protein, is associated with increased risk of mortality and metastasis in various cancer types. The objective of the study was to evaluate the expression of FSCN1 in 312 PAs cases, and to analyze its association with clinicopathologic features and invasion of PAs, thus serving as a promoter of cancer invasion. In non-function PAs (NFPA), FSCN1 nuclear-positive cases were 53/97 in the invasive group (IPA), and 21/115 in the noninvasive group (nIPA) (x(2) = 30.65, p = 0.004). FSCN1 cytoplasm-positive cases were 36/97 in IPA, and 8/107 in nIPA (x(2) = 29.09, p = 0.000). In growth hormone adenomas (GHomas), FSCN1 nuclear-positive were 10/13 in IPA, and 3/37 in nIPA (x(2) = 23.67, p = 0.000). FSCN1 cytoplasm-positive were 8/13 in IPA, and 2/37 in nIPA (Table 3 x(2) = 18.94, p = 0.000). Overall, a significant difference was found between FSCN1 expression and tumor size (x(2) = 46.21, p = 0.000), not age (x(2) = 2.09, p = 0.148). In the high FSCN1 expression group, 27/137 cases (19.7%) had tumor recurrence, and 10/175 cases (5.7%) in low FSCN1 level (x(2) = 14.40 p = 0.000). Reduction of FSCN1 suppressed the invasion level of GH3 cells through transwells test. In addition, reduction of FSCN1 can obviously down-regulate the level of Notchl and DLL3. Our data may help in deciding whether FSCN1 can be a predictor for invasion and recurrence of PAs. (C) 2015 Elsevier Ireland Ltd. All rights reserved.